Truist Securities has raised its price target for Neurocrine Biosciences, the US-based biopharmaceutical company, citing promising developments in its drug pipeline. The new target, announced on Friday, reflects confidence in the company's late-stage trials for treatments targeting neurological and psychiatric conditions, including tardive dyskinesia and Parkinson's disease.
While Neurocrine is not listed on UK exchanges, the upgrade underscores a broader trend in global biotech investing. UK investors with exposure to US equities through pension funds or ETFs may see indirect benefits. The FTSE 100 closed little changed on Friday at 8,215.4 points, down 0.1%, as traders weighed mixed economic data from China and the US.
Analysts noted that Neurocrine's pipeline strength comes at a time when the biotech sector is facing increased regulatory scrutiny in both the US and Europe. Truist's revised target implies a potential upside of around 15% from current levels, based on the stock's closing price on Thursday. The bank did not provide a new end date for its rating, stating only that it expects continued progress in the coming quarters.
For UK investors, the move highlights the importance of monitoring US biotech developments, as many pension funds hold diversified global equity portfolios. The sector has been volatile in 2026, with the Nasdaq Biotechnology Index down 3% year-to-date amid concerns over drug pricing reforms. However, individual stock upgrades like this can signal confidence in specific therapeutic areas.
Market commentators pointed out that UK-listed biotech firms, such as AstraZeneca and GSK, have also benefited from pipeline optimism this year, though their share price movements are driven by different factors. AstraZeneca shares rose 0.4% on Friday to 12,340p, while GSK edged up 0.2% to 1,720p. The broader healthcare sector on the FTSE 100 gained 0.3% on the day.